Implications of Diminishing Lifespan Marginal Utility for Valuing Equity in Cost-Effectiveness Analysis

被引:0
|
作者
Braithwaite, R. Scott [1 ]
机构
[1] NYU, Grossman Sch Med, Dept Populat Hlth, 227 East 30th St,Sixth Floor, New York, NY 10016 USA
关键词
cost-effectiveness analysis; QALY; utility; inequality-aversion; fairness; TIME TRADE-OFF; STANDARD GAMBLE; HEALTH-CARE; PREFERENCES; DURATION; WEIGHTS; QALYS; AGEISM; MODEL; RATES;
D O I
10.1177/23814683241305106
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction. Diminishing marginal lifespan utility (DMLU) implies that a particular lifespan increment (e.g., 1 life-year) confers lesser marginal utility if added to longer lifespans (e.g., 90 y to 91 y) than to shorter lifespans (e.g., 60 y to 61 y) if quality of life is unchanged. Because DMLU is difficult to disambiguate from discounting, risk attitude, and other elements of utility "curvature," it is poorly characterized. However, the imperative to consider equity in cost-effectiveness analysis (CEA) renders its characterization more important. Methods. I add certainty to the characterization of DMLU through literature review and illustrative example. The literature review synthesizes stated preference studies of utility curvature that exclude risk or probability. The example compares alternative valuations of approaches to reduce inequality in cystic fibrosis outcomes between US centers serving mostly White patients and centers serving mostly non-Black Hispanic patients, with versus without DMLU. Results. The existence of DMLU is likely, and empirical data support its relevance over typical CEA time horizons. The imperative to consider equity in CEA magnifies the importance of DMLU for several reasons. First, intergenerational CEAs require lower discount rates that are less likely to incidentally absorb DMLU. Second, DMLU is incompatible with the use of absolute measures of inequality aversion. Third, DMLU may bias the interpretation of relative measures of inequality aversion toward prioritarianism. Finally, not considering DMLU implicitly biases life-year-based metrics against equity. Conclusion. DMLU is likely to exist, can benefit from additional characterization, and may merit inclusion in CEA alongside discounting. Omitting consideration of DMLU will sometimes confer an antiequity bias and may affect the interpretation of CEAs incorporating inequality aversion.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Valuing cost in cost utility analysis of screening programme
    Vanagas, G
    JOURNAL OF MEDICAL SCREENING, 2004, 11 (04) : 210 - 210
  • [32] Rotator cuff repair: An analysis of utility scores and cost-effectiveness
    Vitale, Mark A.
    Vitale, Michael G.
    Zivin, Joshua G.
    Braman, Jonathan P.
    Bigliani, Louis U.
    Flatow, Evan L.
    JOURNAL OF SHOULDER AND ELBOW SURGERY, 2007, 16 (02) : 181 - 187
  • [33] COMPARISON OF HEALTH STATE UTILITY ESTIMATES IN COST-EFFECTIVENESS ANALYSIS
    Slejko, J. F.
    Ghushchyan, V. H.
    Sullivan, P. W.
    VALUE IN HEALTH, 2010, 13 (03) : A13 - A13
  • [34] IMPLICATIONS COR COST-EFFECTIVENESS
    PAUL, SD
    AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (16): : 1125 - 1125
  • [35] INCREASING LIFE EXPECTANCY: IMPLICATIONS FOR COST-EFFECTIVENESS ANALYSIS
    Majer, I. M.
    Heeg, B.
    VALUE IN HEALTH, 2012, 15 (07) : A468 - A468
  • [36] Adjusting to changes in health: implications for cost-effectiveness analysis
    Sharma, R
    Stano, M
    Haas, M
    JOURNAL OF HEALTH ECONOMICS, 2004, 23 (02) : 335 - 351
  • [37] Cost-effectiveness analysis in radiology: methods, results and implications
    Froelich, Matthias F.
    Kunz, Wolfgang G.
    Tollens, Fabian
    Schnitzer, Moritz L.
    Schoenberg, Stefan O.
    Kaiser, Clemens G.
    Ruebenthaler, Johannes
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2021, : 29 - 37
  • [38] WILL COST-EFFECTIVENESS ANALYSIS WORSEN THE COST-EFFECTIVENESS OF CARE
    HIMMELSTEIN, DU
    WOOLHANDLER, S
    BOR, DH
    CLINICAL RESEARCH, 1987, 35 (03): : A744 - A744
  • [39] Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation
    Keown, P
    TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) : 1140 - 1141
  • [40] Posttransplant Hepatocellular Carcinoma Surveillance A Cost-effectiveness and Cost-utility Analysis
    Hessheimer, Amelia J.
    Vargas-Martinez, Ana Magdalena
    Trapero-Bertran, Marta
    Navasa, Miquel
    Fondevila, Constantino
    ANNALS OF SURGERY, 2023, 277 (02) : E359 - E365